Cart
sales@molnova.com
THZ-1
CAS No. 1604810-83-4
THZ-1 ( CDK7 inhibitor )
Catalog No. M12303 CAS No. 1604810-83-4
A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 73 | In Stock |
|
| 10MG | 126 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 332 | In Stock |
|
| 100MG | 448 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTHZ-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.
-
DescriptionA potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM; causes decreased cellular proliferation and an increase in apoptotic index (MCL-1, XIAP), disproportionally affects transcription of RUNX1 in Jurkat T-ALL cells; demonstrates efficacy against primary leukemia cells and in a bioluminescent xenografted model at 10mg/kg.
-
SynonymsCDK7 inhibitor
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK7
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1604810-83-4
-
Formula Weight566.05
-
Molecular FormulaC31H28ClN7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 27 mg/mL
-
SMILESCN(C)CC=CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl
-
Chemical NameBenzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kwiatkowski N, et al. Nature. 2014 Jul 31;511(7511):616-20.
2. Chipumuro E, et al. Cell. 2014 Nov 20;159(5):1126-39.
3. Christensen CL, et al. Cancer Cell. 2014 Dec 8;26(6):909-22.
2. Chipumuro E, et al. Cell. 2014 Nov 20;159(5):1126-39.
3. Christensen CL, et al. Cancer Cell. 2014 Dec 8;26(6):909-22.
molnova catalog
related products
-
CDK12-IN-2
CDK12-IN-2 is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CDK12.
-
BS-181
BS-181 is a potent, selective CDK7 inhibitor with IC50 of 21 nM.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
